SAN DIEGO, Dec. 21, 2020 /PRNewswire/ -- Evofem Biosciences,
Inc., (NASDAQ: EVFM) today announced it will present at
the H.C. Wainwright BIOCONNECT 2021 Virtual Conference.
Evofem's CEO, Saundra Pelletier, will provide updates on
the commercialization of Phexxi® (lactic acid, citric acid and
potassium bitartrate), the first and only FDA-approved, hormone
free contraceptive vaginal gel, and the pivotal Phase 3
EVOGUARD trial, which is evaluating EVO100 for the prevention
of chlamydia and gonorrhea in women and currently enrolling
subjects at study centers across the U.S.
The presentation will be available for on-demand listening
beginning Monday, January 11,
2021, at 6:00 AM Eastern Time
on the Investors section of the Evofem Biosciences website
at www.evofem.com, under the Events and
Presentations tab.
About Evofem Biosciences
Evofem Biosciences, Inc.,
(NASDAQ: EVFM) is a commercial-stage biopharmaceutical company
committed to developing and commercializing innovative products to
address unmet needs in women's sexual and reproductive health,
including hormone-free, woman-controlled contraception and
protection from certain sexually transmitted infections (STIs). The
Company's first commercial product, Phexxi® (lactic acid, citric
acid and potassium bitartrate), is the first and only hormone-free,
prescription vaginal gel approved in the United
States for the prevention of pregnancy. The Company is
evaluating EVO100 in a Phase 3 clinical
trial, 'EVOGUARD,' for the prevention of urogenital
Chlamydia trachomatis and Neisseria
gonorrhoeae infection in women. For more information,
please visit www.evofem.com.
Phexxi® is a registered trademark of Evofem Biosciences,
Inc.
Investor Relations Contact
Amy
Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775
Media Contact
Ellen
Thomas
Evofem Biosciences, Inc.
ethomas@evofem.com
Mobile: (718) 490-3248
View original content to download
multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-the-hc-wainwright-bioconnect-2021-virtual-conference-301196515.html
SOURCE Evofem Biosciences, Inc.